When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Miracle Healing Peptide or Hidden Danger? Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review FDA Peptide Reclassification 2026: What It Means for Providers Peptides, Drugs And Supplements: Science, Risks, And Alternatives Los Angeles Times